Literature DB >> 22105950

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

Kottil W Rammohan, Milissa R Ortega, Silvia R Delgado, Leticia Tornes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22105950     DOI： 10.1212/WNL.0b013e31823c1200

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  2 in total

Review 1.  Natalizumab in Multiple Sclerosis: Long-Term Management.

Authors:  Marinella Clerico; Carlo Alberto Artusi; Alessandra Di Liberto; Simona Rolla; Valentina Bardina; Pierangelo Barbero; Stefania Federica De Mercanti; Luca Durelli
Journal:  Int J Mol Sci       Date:  2017-04-29       Impact factor: 5.923

2.  PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.

Authors:  Clara G Chisari; Giancarlo Comi; Massimo Filippi; Damiano Paolicelli; Pietro Iaffaldano; Mauro Zaffaroni; Vincenzo Brescia Morra; Eleonora Cocco; Girolama Alessandra Marfia; Luigi Maria Grimaldi; Matilde Inglese; Simona Bonavita; Alessandra Lugaresi; Giuseppe Salemi; Giovanna De Luca; Salvatore Cottone; Antonella Conte; Patrizia Sola; Umberto Aguglia; Giorgia Teresa Maniscalco; Claudio Gasperini; Maria Teresa Ferrò; Ilaria Pesci; Maria Pia Amato; Marco Rovaris; Claudio Solaro; Giacomo Lus; Davide Maimone; Roberto Bergamaschi; Franco Granella; Alessia Di Sapio; Antonio Bertolotto; Rocco Totaro; Marika Vianello; Paola Cavalla; Paolo Bellantonio; Vito Lepore; Francesco Patti
Journal:  J Neurol       Date:  2021-06-28       Impact factor: 4.849
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.